ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB – Get Free Report) was the recipient of a significant decline in short interest in August. As of August 31st, there was short interest totalling 8,700 shares, a decline of 5.4% from the August 15th total of 9,200 shares. Based on an average daily trading volume, of 13,900 shares, the short-interest ratio is presently 0.6 days.
Hedge Funds Weigh In On ProShares Ultra Nasdaq Biotechnology
A number of institutional investors and hedge funds have recently added to or reduced their stakes in BIB. Clarity Capital Partners LLC acquired a new position in shares of ProShares Ultra Nasdaq Biotechnology during the fourth quarter worth approximately $201,000. Texas Capital Bank Wealth Management Services Inc acquired a new position in shares of ProShares Ultra Nasdaq Biotechnology during the first quarter worth approximately $288,000. Westwood Wealth Management acquired a new position in shares of ProShares Ultra Nasdaq Biotechnology during the first quarter worth approximately $575,000. Toth Financial Advisory Corp lifted its position in shares of ProShares Ultra Nasdaq Biotechnology by 132.3% during the first quarter. Toth Financial Advisory Corp now owns 26,111 shares of the exchange traded fund’s stock worth $1,502,000 after purchasing an additional 14,870 shares in the last quarter. Finally, IMC Chicago LLC acquired a new position in shares of ProShares Ultra Nasdaq Biotechnology during the fourth quarter worth approximately $2,435,000.
ProShares Ultra Nasdaq Biotechnology Stock Performance
NASDAQ:BIB opened at $67.26 on Wednesday. ProShares Ultra Nasdaq Biotechnology has a 12 month low of $40.10 and a 12 month high of $69.56. The company’s 50-day moving average price is $65.16 and its two-hundred day moving average price is $59.24.
ProShares Ultra Nasdaq Biotechnology Increases Dividend
About ProShares Ultra Nasdaq Biotechnology
ProShares Ultra Nasdaq Biotechnology (the Fund) seeks daily investment results, before fees and expenses, that correspond to twice (200%) the daily performance of the Index. The return of the Fund for a period longer than a single trading day will be the result of each day’s returns compounded over the period, which will very likely differ from the inverse of the return of the Dow Jones United States Basic Materials Index (the Index) for that period.
Read More
- Five stocks we like better than ProShares Ultra Nasdaq Biotechnology
- What is the Shanghai Stock Exchange Composite Index?
- Galmed Pharmaceuticals Surges 400%: What’s Behind the Explosion?
- Most Volatile Stocks, What Investors Need to Know
- Gold Hits New All-Time Highs: 3 Stocks to Ride the Surge
- 3 Stocks to Consider Buying in October
- Intel: Why It’s Time to Reconsider This Beaten-Down Chipmaker
Receive News & Ratings for ProShares Ultra Nasdaq Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProShares Ultra Nasdaq Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.